# EDGAR Filing Document

**Accession Number:** 0001137360
**File Stem:** 0001410368-26-020327
**Filing Date:** 2026-2
**Character Count:** 16684
**Document Hash:** 76fc2e283a168742fce52a4fe231352b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001410368-26-020327.hdr.sgml**: 20260227

**ACCESSION NUMBER**: 0001410368-26-020327

**CONFORMED SUBMISSION TYPE**: NPORT-P

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20251231

**FILED AS OF DATE**: 20260227

**DATE AS OF CHANGE**: 20260227

**PERIOD START**: 20260930

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** VanEck ETF Trust
- **CENTRAL INDEX KEY:** 0001137360

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** NPORT-P
- **SEC ACT:** 1940 Act
- **SEC FILE NUMBER:** 811-10325
- **FILM NUMBER:** 26694367

**BUSINESS ADDRESS:**
- **STREET 1:** 666 THIRD AVENUE, 9TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10017
- **BUSINESS PHONE:** 212-293-2000

**MAIL ADDRESS:**
- **STREET 1:** 666 THIRD AVENUE, 9TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10017

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** VanEck Vectors ETF Trust
- **DATE OF NAME CHANGE:** 20160427

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** MARKET VECTORS ETF TRUST
- **DATE OF NAME CHANGE:** 20070312

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** MARKET VECTORS TRUST
- **DATE OF NAME CHANGE:** 20050516

## Series and Classes Contracts Data

### VanEck Biotech ETF (Series ID: S000034406)

| Class ID   | Class Name         | Ticker Symbol   |
|:---|:---|:---|
| C000105864 | VanEck Biotech ETF | BBH             |

## Nport-Ex

VANECK

BIOTECH

ETF

SCHEDULE

OF

INVESTMENTS

December

31,

2025

(unaudited)

#### FootnoteRuleAboveBlank

#### Footnotes:
\*

See

Schedule

of

Investments

for

geographic

sectors.

#### Number

#### of

#### Shares

#### Value

#### COMMON

#### STOCKS:

#### 99.9%

#### China

#### :

#### 3.2%
BeOne

Medicines

Ltd.

(ADR) \*

†

39,208

$

11,911,783

Underline

#### Germany

#### :

#### 1.8%
BioNTech

SE

(ADR) \*

71,934

6,848,117

Underline

#### Ireland

#### :

#### 2.5%
ICON

PLC

(USD) \*

50,701

9,238,736

Underline

#### United

#### States

#### :

#### 92.4%
Alnylam

Pharmaceuticals,

Inc. \*

41,792

16,618,589

Amgen,

Inc.

173,268

56,712,349

Argenx

SE

(ADR) \*

21,100

17,744,045

Biogen,

Inc. \*

67,436

11,868,062

BioMarin

Pharmaceutical,

Inc. \*

77,097

4,581,875

Bio-Techne

Corp. †

84,129

4,947,626

Charles

River

Laboratories

International,

Inc. \*

26,214

5,229,169

Exact

Sciences

Corp. \*

81,566

8,283,843

Gilead

Sciences,

Inc.

440,313

54,044,018

Illumina,

Inc. \*

74,698

9,797,390

Incyte

Corp. \*

74,488

7,357,180

Insmed,

Inc. \*

89,035

15,495,651

IQVIA

Holdings,

Inc. \*

75,827

17,092,164

Moderna,

Inc. \*

202,391

5,968,511

#### Number

#### of

#### Shares

#### Value

#### United

#### States
(continued)

Natera,

Inc. \*

70,207

$

16,083,722

Neurocrine

Biosciences,

Inc. \*

51,653

7,325,945

QIAGEN

NV †

106,418

4,785,617

Regeneron

Pharmaceuticals,

Inc.

37,632

29,047,012

Repligen

Corp. \*

29,983

4,913,014

Tempus

AI,

Inc. \*

†

69,371

4,096,357

United

Therapeutics

Corp. \*

22,934

11,174,591

Vertex

Pharmaceuticals,

Inc. \*

75,637

34,290,790

347,457,520

#### Total

#### Common

#### Stocks
(Cost:

$339,264,830)

375,456,156

#### SHORT-TERM

#### INVESTMENT

#### HELD

#### AS

#### COLLATERAL

#### FOR

#### SECURITIES

#### ON

#### LOAN:

#### 0.6%

#### Money

#### Market

#### Fund:

#### 0.6%
(Cost:

$2,165,142)

State

Street

Navigator

Securities

Lending

Government

Money

Market

Portfolio

3.80%(a)

2,165,142

2,165,142

#### Total

#### Investments:

#### 100.5%
(Cost:

$341,429,972)

377,621,298

#### Liabilities

#### in

#### excess

#### of

#### other

#### assets:

#### (0.5)%
(1,799,615)

#### NET

#### ASSETS:

#### 100.0%
$

375,821,683

#### Definitions:
ADR

American

Depositary

Receipt

USD

United

States

Dollar

†

Security

fully

or

partially

on

loan.

Total

market

value

of

securities

on

loan

is

$17,845,639.

\*

Non-income

producing

(a) Rate

shown

is

the

7-day

yield

as

of

12/31/25.

The

summary

of

inputs

used

to

value

the

Fund's

investments

as

of

December

31,

2025

is

as

follows:

#### Level

#### 1

#### Quoted

#### Prices

#### Level

#### 2

#### Significant

#### Observable

#### Inputs

#### Level

#### 3

#### Significant

#### Unobservable

#### Inputs

#### Value
Common

Stocks

\*

$

375,456,156

$

—

$

—

$

375,456,156

Money

Market

Fund

2,165,142

—

—

2,165,142

#### Total

#### Investments
$

377,621,298

$

—

$

—

$

377,621,298

## Form NPORT-P: Monthly Portfolio Investments Report

### NPORT-P: Part A: General Information

**Item A.1. Information about the Registrant.**

- **a. Name of Registrant:** VanEck ETF Trust

- **b. Investment Company Act file number:** 811-10325

- **c. CIK number of Registrant:** 0001137360

- **d. LEI of Registrant:** 549300ZLFKNTXC51ZN76

- **e. Address and telephone number of Registrant.**

  - **Street Address 1:** 666 THIRD AVENUE, 9TH FLOOR

  - **City:** NEW YORK

  - **State:** NY

  - **Foreign country:** US

  - **Zip / Postal Code:** 10017

  - **Telephone number:** 212-293-2000

**Item A.2. Information about the Series.**

- **a. Name of Series:** VanEck Biotech ETF

- **b. EDGAR series identifier (if any):** S000034406

- **c. LEI of Series:** 549300PGHG6VYS4R2K51

**Item A.3. Reporting period.**

- **a. Date of fiscal year-end:** 2026-09-30

- **b. Date as of which information is reported:** 2025-12-31

**Item A.4. Final filing**

Does the Fund anticipate that this will be its final filing on Form N-PORT? **No**

### Fund Information

**Total Assets:** $378160653.30

**Total Liabilities:** $2339108.29

**Net Assets:** $375821545.01

**Cash Not Reported:** $540985.71

**Monthly Return Information**

| Class               | Month 1 Return (%)   | Month 2 Return (%)   | Month 3 Return (%)   |
|:---|:---|:---|:---|
| Class ID C000105864 | 9.31%                | 9.14%                | -3.81%               |

**Monthly Gains & Losses**

| Period   | Net Realized Gain/Loss   | Net Unrealized Appreciation/Depreciation   |
|:---|:---|:---|
| Month 1  | $5266395.51              | $26385708.60                               |
| Month 2  | $1105368.73              | $31322339.92                               |
| Month 3  | $-3001740.93             | $-11900350.09                              |

### Schedule of Portfolio Investments

| Name                                         | Title                                                                       | Identifiers                                   | Payoff Profile   | Asset Category   | Issuer Category   | Country   |   Balance | Units   | Value (USD)   | % of Net Assets   | Maturity Date   | Coupon Type   | Annualized Rate (%)   | Restricted?   |   Fair Value Level | Lending Status   |
|:---|:---|:---|:---|:---|:---|:---|---:|:---|:---|:---|:---|:---|:---|:---|---:|:---|
| Alnylam Pharmaceuticals Inc                  | Alnylam Pharmaceuticals Inc                                                 | CUSIP: 02043Q107<br>LEI: 529900S3ZI14OWRJII50 | Long             | EC               | CORP              | US        |     41792 | NS      | $16618588.80  | 4.42%             |  |  |  | No            |                  1 | On Loan: No      |
| Amgen Inc                                    | Amgen Inc                                                                   | CUSIP: 031162100<br>LEI: 62QBXGPJ34PQ72Z12S66 | Long             | EC               | CORP              | US        |    173268 | NS      | $56712349.08  | 15.09%            |  |  |  | No            |                  1 | On Loan: No      |
| Argenx SE                                    | Argenx SE                                                                   | CUSIP: 04016X101<br>LEI: 7245009C5FZE6G9ODQ71 | Long             | EC               | CORP              | NL        |     21100 | NS      | $17744045.00  | 4.72%             |  |  |  | No            |                  1 | On Loan: No      |
| BeOne Medicines Ltd                          | BeOne Medicines Ltd                                                         | CUSIP: 07725L102<br>LEI: 549300JFUK6FRD5MH739 | Long             | EC               | CORP              | CH        |     39208 | NS      | $11911782.48  | 3.17%             |  |  |  | No            |                  1 | On Loan: —       |
| BioMarin Pharmaceutical Inc                  | BioMarin Pharmaceutical Inc                                                 | CUSIP: 09061G101<br>LEI: NSLL8ITTRR0J5HEMR848 | Long             | EC               | CORP              | US        |     77097 | NS      | $4581874.71   | 1.22%             |  |  |  | No            |                  1 | On Loan: No      |
| Biogen Inc                                   | Biogen Inc                                                                  | CUSIP: 09062X103<br>LEI: W8J5WZB5IY3K0NDQT671 | Long             | EC               | CORP              | US        |     67436 | NS      | $11868061.64  | 3.16%             |  |  |  | No            |                  1 | On Loan: No      |
| Bio-Techne Corp                              | Bio-Techne Corp                                                             | CUSIP: 09073M104<br>LEI: 54930073RLKQ51TILZ35 | Long             | EC               | CORP              | US        |     84129 | NS      | $4947626.49   | 1.32%             |  |  |  | No            |                  1 | On Loan: —       |
| BioNTech SE                                  | BioNTech SE                                                                 | CUSIP: 09075V102<br>LEI: 894500UZJ5LG1F8J1U58 | Long             | EC               | CORP              | DE        |     71934 | NS      | $6848116.80   | 1.82%             |  |  |  | No            |                  1 | On Loan: No      |
| Charles River Laboratories International Inc | Charles River Laboratories International Inc                                | CUSIP: 159864107<br>LEI: 549300BSQ0R4UZ5KX287 | Long             | EC               | CORP              | US        |     26214 | NS      | $5229168.72   | 1.39%             |  |  |  | No            |                  1 | On Loan: No      |
| Exact Sciences Corp                          | Exact Sciences Corp                                                         | CUSIP: 30063P105<br>LEI: 549300VM3X1FYD4N9Z14 | Long             | EC               | CORP              | US        |     81566 | NS      | $8283842.96   | 2.20%             |  |  |  | No            |                  1 | On Loan: No      |
| Gilead Sciences Inc                          | Gilead Sciences Inc                                                         | CUSIP: 375558103<br>LEI: 549300WTZWR07K8MNV44 | Long             | EC               | CORP              | US        |    440313 | NS      | $54044017.62  | 14.38%            |  |  |  | No            |                  1 | On Loan: No      |
| Illumina Inc                                 | Illumina Inc                                                                | CUSIP: 452327109<br>LEI: SQ95QG8SR5Q56LSNF682 | Long             | EC               | CORP              | US        |     74698 | NS      | $9797389.68   | 2.61%             |  |  |  | No            |                  1 | On Loan: No      |
| Incyte Corp                                  | Incyte Corp                                                                 | CUSIP: 45337C102<br>LEI: 549300Z4WN6JVZ3T4680 | Long             | EC               | CORP              | US        |     74488 | NS      | $7357179.76   | 1.96%             |  |  |  | No            |                  1 | On Loan: No      |
| Insmed Inc                                   | Insmed Inc                                                                  | CUSIP: 457669307<br>LEI: 529900Q55QAG41CCAC11 | Long             | EC               | CORP              | US        |     89035 | NS      | $15495651.40  | 4.12%             |  |  |  | No            |                  1 | On Loan: No      |
| IQVIA Holdings Inc                           | IQVIA Holdings Inc                                                          | CUSIP: 46266C105<br>LEI: 549300W3R20NM4KQPH86 | Long             | EC               | CORP              | US        |     75827 | NS      | $17092164.07  | 4.55%             |  |  |  | No            |                  1 | On Loan: No      |
| Moderna Inc                                  | Moderna Inc                                                                 | CUSIP: 60770K107<br>LEI: 549300EI6OKH5K5Q2G38 | Long             | EC               | CORP              | US        |    202391 | NS      | $5968510.59   | 1.59%             |  |  |  | No            |                  1 | On Loan: No      |
| Natera Inc                                   | Natera Inc                                                                  | CUSIP: 632307104<br>LEI: 529900CQ3OZ0A0VYVU59 | Long             | EC               | CORP              | US        |     70207 | NS      | $16083721.63  | 4.28%             |  |  |  | No            |                  1 | On Loan: No      |
| Neurocrine Biosciences Inc                   | Neurocrine Biosciences Inc                                                  | CUSIP: 64125C109<br>LEI: 549300FECER0XBN49756 | Long             | EC               | CORP              | US        |     51653 | NS      | $7325944.99   | 1.95%             |  |  |  | No            |                  1 | On Loan: No      |
| Regeneron Pharmaceuticals Inc                | Regeneron Pharmaceuticals Inc                                               | CUSIP: 75886F107<br>LEI: 549300RCBFWIRX3HYQ56 | Long             | EC               | CORP              | US        |     37632 | NS      | $29047011.84  | 7.73%             |  |  |  | No            |                  1 | On Loan: No      |
| Repligen Corp                                | Repligen Corp                                                               | CUSIP: 759916109<br>LEI: 54930006QJ0T5AUO1E71 | Long             | EC               | CORP              | US        |     29983 | NS      | $4913014.38   | 1.31%             |  |  |  | No            |                  1 | On Loan: No      |
| Tempus AI Inc                                | Tempus AI Inc                                                               | CUSIP: 88023B103<br>LEI: 2549009LA0KWRAGQBX50 | Long             | EC               | CORP              | US        |     69371 | NS      | $4096357.55   | 1.09%             |  |  |  | No            |                  1 | On Loan: —       |
| United Therapeutics Corp                     | United Therapeutics Corp                                                    | CUSIP: 91307C102<br>LEI: 5299005C4HZL4UWROC14 | Long             | EC               | CORP              | US        |     22934 | NS      | $11174591.50  | 2.97%             |  |  |  | No            |                  1 | On Loan: No      |
| Vertex Pharmaceuticals Inc                   | Vertex Pharmaceuticals Inc                                                  | CUSIP: 92532F100<br>LEI: 54930015RAQRRZ5ZGJ91 | Long             | EC               | CORP              | US        |     75637 | NS      | $34290790.32  | 9.12%             |  |  |  | No            |                  1 | On Loan: No      |
| State Street Global Advisors                 | State Street Navigator Securities Lending Government Money Market Portfolio | CUSIP: 857492706<br>LEI: 5493008BJIBKQ5KTIF74 | Long             | STIV             | RF                | US        |   2160077 | NS      | $2160076.75   | 0.57%             |  |  |  | No            |                  1 | On Loan: No      |
| ICON PLC                                     | ICON PLC                                                                    | CUSIP: 000000000<br>LEI: 6354008SRQGEMC4XFI67 | Long             | EC               | CORP              | IE        |     50701 | NS      | $9238736.22   | 2.46%             |  |  |  | No            |                  1 | On Loan: No      |
| QIAGEN NV                                    | QIAGEN NV                                                                   | CUSIP: 000000000<br>LEI: 54930036WK3GMCN17Z57 | Long             | EC               | CORP              | NL        |    106418 | NS      | $4785617.46   | 1.27%             |  |  |  | No            |                  1 | On Loan: —       |

### Signature

**Date Signed:** 2026-01-30

**Name of Applicant:** VanEck ETF Trust

**Signature:** James Parker

**Name of Signer:** James Parker

**Title:** Assistant Treasurer